Previous studies suggest that SMAD4 acts as a tumor metastatic suppressor in the exquisite context of PTEN-loss mouse models for PCa [29, 30], whereas TGFβ/SMAD4 activation has also been reported to promote metastatic progression of cancers including PCa [31, 32]. Here, SMAD4 is linked to cancer.